ORBIMED ADVISORS LLC
Q1 2021 13F-HR Holdings
Net value change ($000)
-733,114
(-6.4%)
New positions
32
Sold out positions
27
Turnover %
24.7%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q4 2020
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| EWTX | 453,202 | NEW |
| Gracell Biotechnologies Inc. | 121,427 | NEW |
| HAE | 94,581 | NEW |
| XTNT | 84,901 | 97.5% |
| TERN | 83,406 | NEW |
| IMA | 82,884 | NEW |
| GH | 79,837 | 115.1% |
| IRON | 78,945 | NEW |
| CMMB | 74,019 | NEW |
| MRK | 70,200 | 32.3% |
Top Reduces (Value $000, Stocks/ETFs)
| PRLD | -680,793 | -61.0% |
| Prevail Therapeutics Inc. | -318,884 | -100.0% |
| PMVP | -209,796 | -46.5% |
| PFE | -133,127 | -100.0% |
| CNC | -119,682 | -100.0% |
| Turning Point Therapeutics, Inc. | -111,160 | -33.2% |
| CALC | -106,782 | -82.2% |
| BIIB | -106,689 | -82.3% |
| IOVA | -97,949 | -31.8% |
| AGIO | -95,643 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
29,567
(0.3% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|